Patents by Inventor Kirk McLean
Kirk McLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11016483Abstract: A system and method for operating an indoor/outdoor drone in a training mode that limits the maximum altitude during flight, restricts the ability to perform rapid maneuvers, and also may disable the ability to conduct aerial stunts. The system includes a flight controller that may select between the training mode, a normal mode, and a stunt mode. In the training mode, the flight controller restricts an increase in altitude of the drone beyond an altitude threshold, and also restricts an increase in one or more movement parameters of the drone beyond respective movement parameter thresholds. The selection of the training mode may disable the ability for the user to select the stunt mode.Type: GrantFiled: June 12, 2018Date of Patent: May 25, 2021Assignee: MerchSource, LLCInventors: Kirk McLean, Lisa Nguyen, Michael Gerstner
-
Publication number: 20180356816Abstract: A system and method for operating an indoor/outdoor drone in a training mode that limits the maximum altitude during flight, restricts the ability to perform rapid maneuvers, and also may disable the ability to conduct aerial stunts. The system includes a flight controller that may select between the training mode, a normal mode, and a stunt mode. In the training mode, the flight controller restricts an increase in altitude of the drone beyond an altitude threshold, and also restricts an increase in one or more movement parameters of the drone beyond respective movement parameter thresholds. The selection of the training mode may disable the ability for the user to select the stunt mode.Type: ApplicationFiled: June 12, 2018Publication date: December 13, 2018Inventors: Kirk McLean, Lisa Nguyen, Michael Gerstner
-
Patent number: 10035840Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: GrantFiled: July 28, 2016Date of Patent: July 31, 2018Assignee: Bayer HealthCare LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk McLean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20170218035Abstract: Compositions and methods are provided for therapeutic treatment using recombinant Hemopexin molecules having sufficient sialyation and/or absence of neutral glycans to allow for sufficient circulation to remove free heme from a biological organism. In other embodiments, a recombinant Hemopexin molecule is provided for therapeutic treatment having a percentage of neutral glycans to total glycans in a range of from about 2 to about 30 percent as measured by HPLC after labelling with fluorescent probe 2-aminobenzoic acid. Methods of treatment and making a recombinant Hemopexin molecule are also described.Type: ApplicationFiled: September 29, 2015Publication date: August 3, 2017Applicant: Bayer HealthCare LLCInventors: Kirk MCLEAN, Terry HERMISTON, Alan BROOKS, Richard FELDMAN
-
Publication number: 20170051042Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: July 28, 2016Publication date: February 23, 2017Inventors: Richard FELDMAN, Ji-Yun KIM, Haiyan JIANG, Kirk MCLEAN, Junliang PAN, Glenn PIERCE, James WU, Xiao-Yan ZHAO
-
Patent number: 9422362Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: GrantFiled: April 15, 2014Date of Patent: August 23, 2016Assignee: BAYER HEALTHCARE LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20150307625Abstract: Provided herein are antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human activated Protein C (aPC) with minimal binding to its zymogen Protein C (PC). Moreover, these aPC binding proteins could potentially block the anti-coagulant activity of aPC to induce coagulation. Therapeutic uses of these binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: November 27, 2013Publication date: October 29, 2015Applicant: BAYER HEALTHCARE LLCInventors: Xiao-Yan ZHAO, Zhuozhi WANG, Jian-Ming GU, Ji-Yun KIM, Maxine BAUZON, John E. MURPHY, Kirk MCLEAN, Fang JIN, Tobias MARQUARDT, Xinquan WANG, Andreas WILMEN
-
Publication number: 20140221618Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Patent number: 8501185Abstract: Dimeric molecular complexes useful for diagnostics and therapeutics.Type: GrantFiled: May 24, 2007Date of Patent: August 6, 2013Assignee: Bayer Healthcare LLCInventors: Tara Renee Heitner Hansen, David Light, Kirk McLean, Renate Parry, Noboru Satozawa, Douglas Schneider, Marian Seto
-
Patent number: 7960532Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: July 16, 2009Date of Patent: June 14, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: David Light, Kirk McLean
-
Publication number: 20110104058Abstract: Dimeric molecular complexes comprising an IgE CH4 dimerization domain useful for diagnostics and therapeutics.Type: ApplicationFiled: May 24, 2007Publication date: May 5, 2011Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Tara Heitner, David Light, Kirk McLean, Renate Parry, Noboru Satozawa, Douglas Schneider, Marian Seto
-
Publication number: 20110077202Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: May 15, 2009Publication date: March 31, 2011Applicant: BAYER HEALTHCARE LLCInventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20090317390Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, and inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including, but not limited to, deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: ApplicationFiled: July 16, 2009Publication date: December 24, 2009Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: David Light, Kirk McLean
-
Patent number: 7622122Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: June 21, 2007Date of Patent: November 24, 2009Assignee: Bayer Schering Pharma AktiengesellschaftInventors: David Bruce Light, Kirk McLean
-
Patent number: 7622457Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: June 21, 2007Date of Patent: November 24, 2009Assignee: Bayer Schering Pharma AktiengesellschaftInventors: David Bruce Light, Kirk McLean
-
Patent number: 7579000Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: April 30, 2004Date of Patent: August 25, 2009Assignee: Bayer Schering Pharma AGInventors: David Light, Kirk McLean
-
Publication number: 20080019985Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: ApplicationFiled: June 21, 2007Publication date: January 24, 2008Inventors: David Light, Kirk McLean
-
Publication number: 20080020965Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: ApplicationFiled: June 21, 2007Publication date: January 24, 2008Inventors: David Light, Kirk McLean
-
Patent number: 7250168Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: April 30, 2003Date of Patent: July 31, 2007Assignee: Bayer Schering Pharma AGInventors: David Light, Kirk McLean
-
Publication number: 20060166284Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: ApplicationFiled: April 30, 2003Publication date: July 27, 2006Applicant: CPS COLOR EQUIPMENT S.P.A.Inventors: David Light, Kirk McLean